Two Sigma Investments’s Harpoon Therapeutics, Inc. Common Stock HARP Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q1
Sell
-27,042
Closed -$307K 3511
2023
Q4
$307K Buy
+27,042
New +$213K ﹤0.01% 2687
2023
Q3
Sell
-4,314
Closed -$30.6K 3364
2023
Q2
$30.6K Sell
4,314
-1,394
-24% -$9.64K ﹤0.01% 2876
2023
Q1
$42.5K Buy
+5,708
New +$48K ﹤0.01% 2778
2022
Q4
Sell
-3,336
Closed -$32K 3172
2022
Q3
$32K Buy
3,336
+1,415
+74% +$26.4K ﹤0.01% 2352
2022
Q2
$37K Buy
+1,921
New +$49.8K ﹤0.01% 2365
2022
Q1
Sell
-11,744
Closed -$887K 4688
2021
Q4
$887K Sell
11,744
-28,903
-71% -$1.97M ﹤0.01% 2669
2021
Q3
$3.21M Buy
+40,647
New +$4.09M 0.01% 1561
2020
Q4
Sell
-2,880
Closed -$489K 3883
2020
Q3
$489K Sell
2,880
-22
-0.8% -$3.17K ﹤0.01% 2267
2020
Q2
$482K Sell
2,902
-1,121
-28% -$175K ﹤0.01% 2021
2020
Q1
$466K Buy
4,023
+68
+2% +$9.56K ﹤0.01% 1987
2019
Q4
$585K Buy
+3,955
New +$600K ﹤0.01% 2664

Two Sigma Investments's HARP Position: Q1 2024 in Review

Two Sigma Investments sold out of Harpoon Therapeutics, Inc. Common Stock (HARP) in Q1 2024, closing a stake of 27,042 shares — an estimated $307K sold.

Two Sigma Investments first reported a position in HARP in Q4 2019 and held it in 11 quarters. The position peaked at $3.21M in Q3 2021. 0 funds tracked by Wall St. Rank hold HARP as of Q1 2024.

  • Two Sigma Investments reported no remaining Harpoon Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • Two Sigma Investments sold 27,042 Harpoon Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $307K.
  • Two Sigma Investments first reported a position in Harpoon Therapeutics, Inc. Common Stock in Q4 2019 and held it in 11 quarters.
  • Two Sigma Investments's Harpoon Therapeutics, Inc. Common Stock position peaked at $3.21M in Q3 2021.
  • 0 funds tracked by Wall St. Rank held Harpoon Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Two Sigma Investments's 13F filing for Q1 2024, filed 15 May 2024.